Focus on: Biomarkers, MRI and PSMA PET Imaging in Prostate Cancer
150AB
Focus On Session
Information
New for 2026, Focus on: are a series of accredited sessions offering an in-depth exploration of key clinical topics aligned with AUA’s ongoing needs assessments. This session provides a deeper dive for the urologic care team to examine how emerging biomarkers, advanced MRI techniques, and PSMA PET imaging are reshaping prostate cancer care.
Learning Objectives:
After participating in this CME activity, participants will be able to:
1. Critically appraise recent developments in imaging biomarkers and molecular diagnostics (e.g., genomic risk scores, liquid biopsy) and discuss how they complement MRI and PSMA PET in prostate cancer care.
2. Determine the optimal clinical scenarios (diagnostic, staging, recurrence, surveillance) in which PSMA PET/CT or PET/MRI adds value beyond conventional imaging.
3. Recognize potential pitfalls in PSMA PET interpretation — including false positives, false negatives, non–PSMA-expressing disease, and technical artifacts — and implement strategies to mitigate them.
4. Synthesize biomarker, MRI, and PSMA PET findings into a personalized management plan, including guiding biopsy, focal therapy, salvage therapy, or systemic treatments.
5. Select appropriate patients with radiorecurrent or organ-confined prostate cancer for advanced imaging and guide re-treatment decisions (e.g., salvage therapy, targeted radiotherapy).
Learning Objectives:
After participating in this CME activity, participants will be able to:
1. Critically appraise recent developments in imaging biomarkers and molecular diagnostics (e.g., genomic risk scores, liquid biopsy) and discuss how they complement MRI and PSMA PET in prostate cancer care.
2. Determine the optimal clinical scenarios (diagnostic, staging, recurrence, surveillance) in which PSMA PET/CT or PET/MRI adds value beyond conventional imaging.
3. Recognize potential pitfalls in PSMA PET interpretation — including false positives, false negatives, non–PSMA-expressing disease, and technical artifacts — and implement strategies to mitigate them.
4. Synthesize biomarker, MRI, and PSMA PET findings into a personalized management plan, including guiding biopsy, focal therapy, salvage therapy, or systemic treatments.
5. Select appropriate patients with radiorecurrent or organ-confined prostate cancer for advanced imaging and guide re-treatment decisions (e.g., salvage therapy, targeted radiotherapy).
Continuing Medical Education
CME
Format
On-Demand
Documents & Links
Course Handouts
Registered attendees
Patrick Michael
FellowNCI/NIH